Thromb Haemost 2004; 91(01): 196-197
DOI: 10.1055/s-0037-1614256
Case Report
Schattauer GmbH

Skin necrosis is a clinical manifestation of low-molecular weight heparin-induced thrombocytopenia

Pierre Fontana
1   Françoise Boehlen, Victor Janer, Gürkan Kaya, Marc Righini
,
Alexandre Bodmer
1   Françoise Boehlen, Victor Janer, Gürkan Kaya, Marc Righini
,
Yves Gruel
1   Françoise Boehlen, Victor Janer, Gürkan Kaya, Marc Righini
› Author Affiliations
Further Information

Publication History

Received 26 June 2003

Accepted after resubmission 12 October 2003

Publication Date:
09 December 2017 (online)

 

 
  • References

  • 1 Wutschert R, Piletta P, Bounameaux H. Adverse skin reactions to low molecular weight heparins: frequency, management and prevention. Drug Saf 1999; 20: 515-25.
  • 2 Pouplard C, Amiral J, Borg JY. et al. Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1999; 111: 700-6.
  • 3 Pouplard C, Amiral J, Borg JY. et al. Differences in specificity of heparin-dependent antibodies developed in heparin-induced thrombocytopenia and consequences on crossreactivity with danaparoid sodium. Br J Haematol 1997; 99: 273-80.
  • 4 Gruel Y, Pouplard C, Nguyen P. et al. Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. Br J Haematol 2003; 121: 786-92.
  • 5 Balestra B, Quadri P, Dermarmels FBiasiutti. et al. Low molecular weight heparin-induced thrombocytopenia and skin necrosis distant from injection sites. Eur J Haematol 1994; 53: 61-3.
  • 6 Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344: 1286-92.